TORONTO, Aug. 13 /CNW/ - Patheon Inc. (TSX: PTI), a leading provider of
contract development and manufacturing services to the global pharmaceutical
industry, announced today that it will report its third quarter 2009 financial
results on Monday, September 14, 2009.
In conjunction with this announcement, Patheon will host a conference
call with financial analysts on Monday, September 14, 2009 at 10:00 a.m. (EDT)
to discuss its third quarter 2009 financial results. The third quarter
financial results news release will be issued at approximately 7:00 a.m. (EDT)
on Monday, September 14, 2009.
Interested parties are invited to access the live call, via telephone, in
listen-only mode, at 1-647-427-7450 (Toronto and International) or toll free
at 1-888-231-8191 (U.S., including Puerto Rico). Listeners are encouraged to
dial in five to fifteen minutes in advance to avoid delays. A live audio will
also be available via the web at www.patheon.com. (Please note that Windows
Media Player or RealPlayer is required.)
A telephone replay of the conference call will be available between
Monday, September 14, 2009 and Monday, September 21, 2009 by calling
1-402-220-7738 or 1-888-562-2823 (toll free) and entering identification
number 24957833, followed by the number key. The webcast will also be archived
at www.patheon.com for three months.
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading provider of contract
development and manufacturing services to the global pharmaceutical industry.
Patheon prides itself in providing the highest quality products and services
to more than 300 of the world's leading pharmaceutical and biotechnology
companies. Patheon's services range from preclinical development through
commercial manufacturing of a full array of dosage forms including parenteral,
solid, semi-solid and liquid forms. Patheon uses many innovative technologies
including single-use disposables, liquid-filled hard capsules and a variety of
modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization. Patheon
can take customers direct to clinic with global clinical packaging and
distribution services and Patheon's Quick to Clinic(TM) programs can
accelerate early phase development project to clinical trials while minimizing
the consumption of valuable API.
Patheon's integrated development and manufacturing network of 10
facilities, and 7 development centers across North America and Europe, strives
to ensure that customer products can be launched with confidence anywhere in
For further information:
For further information: Mr. Eric Evans, Chief Financial Officer, Tel:
(919) 226-3204, Email: email@example.com; Ms. Wendy Wilson, Investor
Relations, Tel: (919) 226-3313, Email: firstname.lastname@example.org